Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Amy V Rapkiewicz1, Xingchen Mai2, Steven E Carsons1

  • 1NYU Winthrop Hospital, Chair and Autopsy Director, Department of Pathology, Long Island School of Medicine, 222 Station Plaza North, Suite 618, Mineola, NY, 11501, United States.

Eclinicalmedicine
|August 9, 2020
PubMed

Insights

Autopsies of seven COVID-19 patients revealed widespread platelet-rich thrombi in multiple organs, even with anticoagulation. This suggests early thrombosis plays a key role in COVID-19 pathology.

Area of Science:

  • Pathology
  • Cardiovascular Medicine
  • Infectious Diseases

Background:

  • COVID-19 is increasingly recognized for its prothrombotic state.
  • Post-mortem examinations offer crucial insights into disease mechanisms.

Purpose of the Study:

  • To investigate the role of thrombosis in COVID-19 through autopsy findings.
  • To examine histopathological changes in multiple organs of COVID-19 patients.

Main Methods:

  • Autopsy series of seven COVID-19 patients from a New York academic medical center.
  • Histopathological examination of lungs, heart, kidneys, liver, and bone.
  • Assessment of thrombi, megakaryocytes, and inflammatory markers.

Main Results:

  • All seven patients exhibited platelet-rich thrombi in pulmonary, hepatic, renal, and cardiac microvasculature, irrespective of anticoagulation status.
  • Increased megakaryocytes were observed in the lungs and heart.
  • Diffuse alveolar damage (DAD) was present in all lungs, with superimposed bronchopneumonia in three cases. Renal findings included platelet-fibrin microthrombi and acute tubular necrosis. Cardiac findings included venous thrombosis and myocardial infarction in two cases.

Conclusions:

  • Thrombosis is a prominent feature in multiple organs in COVID-19, occurring early in the disease process.
  • The presence of megakaryocytes and platelet-rich thrombi suggests their involvement in COVID-19-associated thrombosis.
  • Findings indicate thrombosis is a critical component of COVID-19 pathophysiology, potentially independent of disease timing or anticoagulation therapy.
Abstract

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
163
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
259
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.2K